CDK9 and neoplasm: Consistently, dinaciclib blocked CDK2 and CDK9 activity by abolishing the phosphorylation of Rb (Ser807/811) and RNAP II (Ser2) and ultimately induced PARP cleavage in those tumor tissues (Fig. 5d).